US-based biotechnology company Denali Therapeutics has reported that a Phase II/III trial of DNL343 for amyotrophic lateral sclerosis (ALS) failed to meet its primary endpoint. The primary ...

The South San Francisco biotech revealed in January that eIF2B agonist DNL343 was unable to slow disease progression or increase survival compared to placebo at 24 weeks in Regimen G of the phase ...

DNL343 is a novel small molecule ALS therapeutic candidate that targets eIF2B, a central regulator of the integrated stress response. Shares of DNLI have lost 6.5% in the past six months compared ...

The South San Francisco biotech announced that eIF2B agonist DNL343 was unable to slow disease progression or increase survival compared to placebo at 24 weeks in the study, conducted at Sean M ...